$HQY

HealthEquity, Inc. (NASDAQ:HQY) Receives Consensus Rating of "Moderate Buy" from Analysts

HealthEquity, Inc. (NASDAQ:HQY) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of approximately $111.79. The company recently surpassed earnings per share and revenue expectations for its last quarter. Institutional investors hold a significant 99.55% of the stock.

Original reporting
MarketBeat · MarketBeat
Published Apr 25, 2026, 8:36 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 25, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HealthEquity, Inc. (NASDAQ:HQY) Receives Consensus Rating of "Moderate Buy" from Analysts — source image
Decision brief

The 30-second read

$HQYBullishMed
01

Why it matters

The positive analyst sentiment and earnings beat could lead to increased investor confidence, potentially boosting the stock price.

02

Market read

The news is relevant for investors focusing on healthcare and financial sectors, especially those with exposure to US markets.

03

What to watch

Potential upcoming regulatory changes or market shifts that could impact healthcare stocks, which are not addressed in the current analysis.

Timing: short to medium term (next 3-6 months)

Background

HealthEquity, Inc. specializes in health savings accounts and related financial services, operating in a competitive and regulated environment.

Company-level read

Ticker impact

$HQYBullishHigh confidence
Context

Primary focus of the news, significant impact potential.

Expected impact

Moderate upward price movement over the next 3-6 months, contingent on continued earnings performance and analyst sentiment.

Evidence & confidence

The consensus rating, strong institutional ownership, and recent earnings beat support a bullish outlook. However, the 'Moderate Buy' rating indicates some caution among analysts.

Market effects

Potential positive sentiment for the healthcare services and financial sectors, given the company's performance and analyst outlook.

Limited regional impact; primarily relevant to US markets where the company is listed.

Moderate; as a US-based company, its performance may influence global healthcare and financial indices to a minor extent.

Counterpoint

Some analysts may view the 'Moderate Buy' rating as a sign of caution, suggesting waiting for further confirmation before increasing exposure.

Key entities

  • HealthEquity, Inc.

    A provider of health savings accounts and related financial services.

  • Analyst Consensus

    Fifteen brokerages have issued a 'Moderate Buy' rating.

  • Institutional Investors

    Hold 99.55% of the company's stock, indicating strong backing.

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.